S. 932 · 119th Congress (2025–2027)
Give Kids a Chance Act of 2025
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.
Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.
The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.
The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.
GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
Show official title
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is S. 932’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Markwayne Mullin (R-OK)
- Cosponsors
20 cosponsors
1 original · 19 later
10 R · 10 D
- Sen. Michael F. Bennet (D-CO)· Original · Mar 11, 2025
- Sen. Amy Klobuchar (D-MN)· Later · Apr 4, 2025
- Sen. Roger Marshall (R-KS)· Later · Apr 4, 2025
- Sen. Jeanne Shaheen (D-NH)· Later · Apr 4, 2025
- Sen. Susan M. Collins (R-ME)· Later · Apr 8, 2025
- Sen. Rick Scott (R-FL)· Later · Apr 8, 2025
- Sen. Shelley Moore Capito (R-WV)· Later · Oct 23, 2025
- Sen. Christopher A. Coons (D-DE)· Later · Oct 23, 2025
- Sen. Jon Husted (R-OH)· Later · Oct 23, 2025
- Sen. Mark Kelly (D-AZ)· Later · Oct 23, 2025
- Sen. Andy Kim (D-NJ)· Later · Oct 23, 2025
- Sen. Tim Sheehy (R-MT)· Later · Oct 23, 2025
- Sen. John W. Hickenlooper (D-CO)· Later · Oct 30, 2025
- Sen. Ashley Moody (R-FL)· Later · Oct 30, 2025
- Sen. John Boozman (R-AR)· Later · Nov 6, 2025
- Sen. Tammy Duckworth (D-IL)· Later · Nov 6, 2025
- Sen. John Kennedy (R-LA)· Later · Nov 18, 2025
- Sen. Jack Reed (D-RI)· Later · Nov 18, 2025
- Sen. Adam B. Schiff (D-CA)· Later · Nov 18, 2025
- Sen. Eric Schmitt (R-MO)· Later · Nov 19, 2025
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (2)
Give Kids a Chance Act of 2025
Display title, Short title · Introduced in Senate
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Official title · Introduced in Senate